Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 4/20 | 0.56 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.56 |
| ▸ | JAK3 | P52333 | 10/20 | 0.56 |
| ▸ | JAK1 | P23458 | 9/20 | 0.56 |
| ▸ | CDK1 | P06493 | 3/20 | 0.52 |
| ▸ | KDR | P35968 | 3/20 | 0.52 |
| ▸ | PTK2 | Q05397 | 3/20 | 0.52 |
| ▸ | AURKA | O14965 | 2/20 | 0.52 |
| ▸ | SYK | P43405 | 2/20 | 0.52 |
| ▸ | GSK3B | P49841 | 2/20 | 0.52 |
| ▸ | EGFR | P00533 | 2/20 | 0.52 |
| ▸ | BTK | Q06187 | 2/20 | 0.52 |
| ▸ | CDC7 | O00311 | 1/20 | 0.52 |
| ▸ | PLK4 | O00444 | 1/20 | 0.52 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.52 |
| ▸ | DCLK1 | O15075 | 1/20 | 0.52 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.52 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.52 |
| ▸ | JAK2 | O60674 | 1/20 | 0.52 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1476462 | 0.91 | CDK2 (0.56) | CDK2CCNA2JAK3JAK1CDK1 | |
| SCHEMBL1474141 | 0.90 | JAK3 (0.66) | CDK2CCNA2JAK3JAK1CDK1 | |
| SCHEMBL1476480 | 0.89 | JAK3 (0.54) | CDK2CCNA2JAK3JAK1CDK1 | |
| SCHEMBL4000488 | 0.87 | AURKA (0.60) | CDK2CCNA2JAK3JAK1CDK1 | |
| SCHEMBL14780626 | 0.84 | CDK2 (0.58) | CDK2CCNA2JAK3JAK1CDK1 | |
| SCHEMBL1474374 | 0.84 | BRD4 (0.54) | PTK2AURKASYKJAK2FLT3 | |
| SCHEMBL1474839 | 0.82 | JAK3 (0.64) | CDK2CCNA2JAK3JAK1CDK1 | |
| SCHEMBL4975331 | 0.82 | CA2 (0.55) | CDK2CCNA2JAK3JAK1CDK1 | |
| SCHEMBL4972834 | 0.82 | JAK3 (0.56) | CDK2CCNA2JAK3JAK1CDK1 | |
| SCHEMBL1476433 | 0.81 | BRD4 (0.52) | CDK2JAK3JAK1CDK1KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9593082-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2017-03-14 | — | — | US | claimed |
| US-20080221089-A1 | Prevent transplant rejection; autoimmune diseases | RIGEL PHARMACEUTICALS, INC. | 2008-09-11 | — | — | US | claimed |
| US-20070203161-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. | 2007-08-30 | — | — | US | claimed |
| US-11667611-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2023-06-06 | — | — | US | disclosed |
| US-20190256476-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2019-08-22 | — | — | US | disclosed |
| US-20170121291-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2017-05-04 | — | — | US | disclosed |
| US-9593082-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2017-03-14 | — | — | US | disclosed |
| US-7915273-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2011-03-29 | — | — | US | disclosed |
| US-20100152218-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2010-06-17 | — | — | US | disclosed |
| US-20080221089-A1 | Prevent transplant rejection; autoimmune diseases | RIGEL PHARMACEUTICALS, INC. | 2008-09-11 | — | — | US | disclosed |
| WO-2008079907-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2008-07-03 | — | — | WO | disclosed |
| US-20070203161-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. | 2007-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11667611-B2 | Compositions and methods for inhibition of the JAK pathway | JAK3, JAK2, JAK1 | CDK2 236/4885CCNA2 1836/4885JAK3 1/4885 |
| US-20170121291-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | JAK3, JAK2, JAK1 | CDK2 236/4885CCNA2 1836/4885JAK3 1/4885 |
| US-20190256476-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | JAK3, JAK2, JAK1 | CDK2 236/4885CCNA2 1836/4885JAK3 1/4885 |
| US-20070203161-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | JAK3, JAK2, JAK1 | CDK2 236/4885CCNA2 1836/4885JAK3 1/4885 |
| US-20080221089-A1 | Prevent transplant rejection; autoimmune diseases | JAK3, JAK1, JAK2 | CDK2 986/4885CCNA2 3787/4885JAK3 1/4885 |
| US-20100152218-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | JAK3, JAK2, JAK1 | CDK2 236/4885CCNA2 1836/4885JAK3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.